The hormone replacement therapy and the diseases of the arteries;Hormonalna terapia zastepcza a choroby naczyń tetniczych

Przeglad Menopauzalny

Volumn 5, Issue 5, 2006, Pages 274-279

  Debski, Romuald ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Cardiovascular system; Hormone replacement therapy

Indexed keywords

BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; D DIMER; ESTROGEN; GESTAGEN; GLUCOCORTICOID; INTERCELLULAR ADHESION MOLECULE 1; PROGESTERONE; SEX HORMONE; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; EVIDENCE BASED MEDICINE; HEART INFARCTION; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MENOPAUSAL SYNDROME; OUTCOMES RESEARCH; OVARY CYCLE; PATHOGENESIS; PROTEIN BLOOD LEVEL; RISK REDUCTION; SECONDARY PREVENTION; SHORT COURSE THERAPY;

EID: 33845493872     PISSN: 16438876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Writing group for the women's health initiative investigations. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321-33.
2. Writing group of the PEPI trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
3. Million women study collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003; 362: 419-27.
4. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
6. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy (HERS II). JAMA 2002; 288: 49-57.
7. Hoibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy results of the randomized, double-blind, placebo controlled estrogen in venous thromboembolism trial. Thromb Haemost 2000; 84: 961-7.
8. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen replacement therapy after ischemic stroke. N Eng J Med 2001; 345: 1243-9.
9. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long - term effects of hormone replacement therapy. Lancet 2002; 360: 942-4.
10. Collaborative. Group on hormonal factors in breast cancer breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350: 1047-59.
11. Geller ML, Chlebowski RT. HT and breast cancer risk. Sex Reprod Menopause 2003; 1: 5-9.
12. Holst J, Cajander S, Carlstrom K, et al. A comparison of liver protein induction in postmenopausal women during oral and percutaneous oestrogen replacement therapy. Br. J. Obstet Gynaecol 1983; 90: 355-60.
13. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. Arterioscler Thromb Vasc Biol 1997; 17: 3071-8.
14. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001; 75: 898-915.
15. Wakatsuki A, Okatani Y, Ikenoue N, et al. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2002; 106: 1771-6.
16. Langer DL, Pradhan AD, Lewis CE, et al. Baseline associations between postmenopausal hormone therapy and inflamantory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study. Thromb Haemost 2005; 93: 1108-1116.
17. Eilertsen AL, Hoibraaten E, Os I, et al. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 2005; 52: 111-8.
18. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol 2002; 109: 1056-62.
19. Sumino H, Ichikawa S, Ohyama Y, et al. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. Am J Cardiol 2005; 96: 148-53.
20. Sumino H, Ichikawa S, Kasama S, et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res 2005; 28: 579-84.
21. Bukowska H, Stanosz S, Zochowska E, et al. Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women? Metabolism 2005; 54: 72-8.